AR060998A1 - ANTI CD40 MONOCLONAL ANTIBODY HUMAN ANTAGONIST - Google Patents
ANTI CD40 MONOCLONAL ANTIBODY HUMAN ANTAGONISTInfo
- Publication number
- AR060998A1 AR060998A1 ARP070102017A ARP070102017A AR060998A1 AR 060998 A1 AR060998 A1 AR 060998A1 AR P070102017 A ARP070102017 A AR P070102017A AR P070102017 A ARP070102017 A AR P070102017A AR 060998 A1 AR060998 A1 AR 060998A1
- Authority
- AR
- Argentina
- Prior art keywords
- monoclonal antibody
- antibody human
- human antagonist
- antagonist
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Anticuerpos monoclonales anti-CD40 humana antagonistas, métodos para generarlos y usos de los mismos. Reivindicacion 1: Un polipéptido que comprende una secuencia de aminoácidos (Fig. 1) donde: X1 es G, A, V, L, I, P, F, M, W, C, N, Q, S, T, Y, D, E, K, R o H; X2 es G, A, V, L, I, P, F, M, W, C, N, Q, S, T, Y, D, E, K, R o H; X3 es G, A, V, L, I, P, F, M, W, C, N, Q, S, T, Y, D, E, K, R o H; X4 es G, A, V, L, I, P, F, M, W, C, N, Q, S, T, Y, D, E, K, R o H; y X5 es G, A, V, L, I, P, F, M, W, C, N, Q, S, T, Y, D, E, K, R o H.Anti-human CD40 monoclonal antibodies antagonists, methods to generate them and uses thereof. Claim 1: A polypeptide comprising an amino acid sequence (Fig. 1) wherein: X1 is G, A, V, L, I, P, F, M, W, C, N, Q, S, T, Y, D, E, K, R or H; X2 is G, A, V, L, I, P, F, M, W, C, N, Q, S, T, Y, D, E, K, R or H; X3 is G, A, V, L, I, P, F, M, W, C, N, Q, S, T, Y, D, E, K, R or H; X4 is G, A, V, L, I, P, F, M, W, C, N, Q, S, T, Y, D, E, K, R or H; and X5 is G, A, V, L, I, P, F, M, W, C, N, Q, S, T, Y, D, E, K, R or H.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79881906P | 2006-05-09 | 2006-05-09 | |
| EP06076028A EP1854810A1 (en) | 2006-05-09 | 2006-05-09 | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060998A1 true AR060998A1 (en) | 2008-07-30 |
Family
ID=37635851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102017A AR060998A1 (en) | 2006-05-09 | 2007-05-09 | ANTI CD40 MONOCLONAL ANTIBODY HUMAN ANTAGONIST |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8669352B2 (en) |
| EP (2) | EP1854810A1 (en) |
| JP (1) | JP5179474B2 (en) |
| KR (1) | KR101506348B1 (en) |
| CN (1) | CN101490086B (en) |
| AR (1) | AR060998A1 (en) |
| AU (1) | AU2007249031B9 (en) |
| BR (1) | BRPI0711355A2 (en) |
| CA (1) | CA2651565A1 (en) |
| CL (1) | CL2007001335A1 (en) |
| DK (1) | DK2019840T3 (en) |
| ES (1) | ES2406163T3 (en) |
| HK (1) | HK1131627A1 (en) |
| IL (1) | IL195196A (en) |
| MX (1) | MX2008014304A (en) |
| NO (1) | NO20085104L (en) |
| NZ (1) | NZ572756A (en) |
| RU (1) | RU2491295C2 (en) |
| TW (1) | TWI455947B (en) |
| WO (1) | WO2007129895A2 (en) |
| ZA (2) | ZA200810381B (en) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101563363B (en) | 2006-06-21 | 2013-01-02 | 南卡罗来纳医疗大学研究发展基金会 | Targeting complement factor H for treatment of diseases |
| CA2767105A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| CN102712691A (en) | 2009-08-06 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | Method to improve virus removal in protein purification |
| US10239937B2 (en) | 2009-11-05 | 2019-03-26 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
| BR112012024713B1 (en) * | 2010-03-31 | 2021-02-17 | Boehringer Ingelheim International Gmbh | humanized antibody, its uses and pharmaceutical composition that comprises it |
| EA201291241A1 (en) | 2010-05-14 | 2013-05-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт | IMPROVED TARGETS ON RECEPTOR 2 (CR2) GROUP GROUPS |
| MX2012014975A (en) | 2010-06-22 | 2013-03-12 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3. |
| AR083847A1 (en) | 2010-11-15 | 2013-03-27 | Novartis Ag | FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES |
| CA2852056C (en) | 2011-03-11 | 2021-08-10 | Beth Israel Deaconess Medical Center, Inc. | Anti-cd40 antibodies and uses thereof |
| RS57087B1 (en) | 2011-04-21 | 2018-06-29 | Bristol Myers Squibb Co | Antibody polypeptides that antagonize cd40 |
| SG10201610288TA (en) | 2011-10-13 | 2017-02-27 | Bristol Myers Squibb Co | Antibody polypeptides that antagonize cd40l |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| WO2014200349A1 (en) | 2013-06-13 | 2014-12-18 | Fast Forward Pharmaceutical B.V. | Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis. |
| EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
| EP3113796A1 (en) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| SI3178931T1 (en) | 2014-08-07 | 2021-04-30 | Daiichi Sankyo Company, Limited | Anti-orai1 antibody |
| US20170233485A1 (en) * | 2014-08-18 | 2017-08-17 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| CN107249318A (en) | 2014-12-10 | 2017-10-13 | 明尼苏达大学董事会 | For cell, tissue and the organ of the genetic modification for treating disease |
| UA125208C2 (en) | 2015-05-29 | 2022-02-02 | Еббві Інк. | Anti-cd40 antibody |
| CN116063481A (en) | 2015-09-04 | 2023-05-05 | 普里玛托普医疗股份有限公司 | Humanized anti-CD 40 antibodies and uses thereof |
| US10544229B2 (en) | 2015-09-30 | 2020-01-28 | Janssen Biotech, Inc. | Agonistic antibodies specifically binding CD40 and methods of use |
| AU2017281830B2 (en) | 2016-06-20 | 2023-04-06 | Kymab Limited | Anti-PD-L1 antibodies |
| JP2020511959A (en) * | 2017-03-29 | 2020-04-23 | グリコトープ ゲーエムベーハー | Humanized anti-CD40 antibody |
| CA3064298A1 (en) | 2017-06-01 | 2018-12-06 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof |
| CA3076872A1 (en) | 2017-11-03 | 2019-05-09 | Novartis Ag | Anti-cd40 antibodies for use in treatment of sjogren's syndrome |
| EP3752532A1 (en) * | 2018-02-12 | 2020-12-23 | Diabetes-Free, Inc. | Improved antagonistic anti-human cd40 monoclonal antibodies |
| CA3094600A1 (en) | 2018-04-13 | 2019-10-17 | Novartis Ag | Anti-cd40 antibodies for use in prevention of graft rejection |
| CA3097007A1 (en) | 2018-04-20 | 2019-10-24 | Lyvgen Biopharma Co., Ltd. | Anti-cd40 antibodies and uses thereof |
| US20210251994A1 (en) | 2018-06-15 | 2021-08-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| CN116178544A (en) | 2018-09-28 | 2023-05-30 | 礼进生物医药科技（上海）有限公司 | anti-CD 40 binding molecules with engineered Fc domains and therapeutic uses thereof |
| US20210355216A1 (en) | 2018-10-05 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
| WO2020102454A1 (en) | 2018-11-13 | 2020-05-22 | Regents Of The University Of Minnesota | Cd40 targeted peptides and uses thereof |
| KR20210097750A (en) | 2018-11-30 | 2021-08-09 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | CD40 antibody pharmaceutical compositions and uses thereof |
| AU2019389354A1 (en) | 2018-11-30 | 2021-07-15 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment and pharmaceutical use thereof |
| JP2021506953A (en) | 2019-01-11 | 2021-02-22 | ノバルティス アーゲー | Anti-CD40 antibody for use in the treatment of hidradenitis suppurativa |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| BR112021021923A2 (en) | 2019-05-08 | 2022-02-22 | Novartis Ag | Anti-cd40 antibodies for use in the treatment of dm1 and insulitis |
| US20220332836A1 (en) | 2019-09-11 | 2022-10-20 | Novartis Ag | A method for preventing human virus associated disorders in patients |
| EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CN116096906A (en) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | Virus engineered to promote saenox delivery and use thereof in treating cancer |
| EP4284512A1 (en) | 2021-01-28 | 2023-12-06 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| AU2022246895A1 (en) | 2021-03-31 | 2023-10-19 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023020475A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Cd40-targetting antibodies and uses thereof |
| CN117500816A (en) | 2021-08-26 | 2024-02-02 | 映恩生物制药（苏州）有限公司 | Steroid and conjugate thereof |
| WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| DE69334064T2 (en) * | 1992-07-09 | 2007-05-24 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Antagonist monoclonal antibodies to human CD40 |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| WO1998003670A1 (en) | 1996-07-23 | 1998-01-29 | Tanox Pharma B.V. | Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways |
| AU736549B2 (en) * | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| AR039067A1 (en) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
-
2006
- 2006-05-09 EP EP06076028A patent/EP1854810A1/en not_active Withdrawn
-
2007
- 2007-05-09 MX MX2008014304A patent/MX2008014304A/en active IP Right Grant
- 2007-05-09 TW TW096116566A patent/TWI455947B/en not_active IP Right Cessation
- 2007-05-09 CN CN200780025878.9A patent/CN101490086B/en active Active
- 2007-05-09 AR ARP070102017A patent/AR060998A1/en not_active Application Discontinuation
- 2007-05-09 NZ NZ572756A patent/NZ572756A/en not_active IP Right Cessation
- 2007-05-09 BR BRPI0711355-2A patent/BRPI0711355A2/en not_active IP Right Cessation
- 2007-05-09 US US11/801,344 patent/US8669352B2/en active Active
- 2007-05-09 ES ES07747426T patent/ES2406163T3/en active Active
- 2007-05-09 EP EP07747426A patent/EP2019840B1/en active Active
- 2007-05-09 AU AU2007249031A patent/AU2007249031B9/en active Active
- 2007-05-09 WO PCT/NL2007/050202 patent/WO2007129895A2/en active Application Filing
- 2007-05-09 KR KR1020087030080A patent/KR101506348B1/en active IP Right Grant
- 2007-05-09 CA CA002651565A patent/CA2651565A1/en not_active Abandoned
- 2007-05-09 JP JP2009509467A patent/JP5179474B2/en active Active
- 2007-05-09 RU RU2008148303/10A patent/RU2491295C2/en not_active IP Right Cessation
- 2007-05-09 CL CL2007001335A patent/CL2007001335A1/en unknown
- 2007-05-09 DK DK07747426.0T patent/DK2019840T3/en active
- 2007-05-09 ZA ZA200810381A patent/ZA200810381B/en unknown
-
2008
- 2008-11-10 IL IL195196A patent/IL195196A/en active IP Right Grant
- 2008-12-09 NO NO20085104A patent/NO20085104L/en not_active Application Discontinuation
-
2009
- 2009-11-30 HK HK09111185.3A patent/HK1131627A1/en not_active IP Right Cessation
- 2009-12-23 ZA ZA2009/09185A patent/ZA200909185B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060998A1 (en) | ANTI CD40 MONOCLONAL ANTIBODY HUMAN ANTAGONIST | |
| ES2564252T3 (en) | Anti-beta-amyloid N3pGlu peptide antibodies and uses thereof | |
| AR065083A1 (en) | HEPCIDINE, HEPCIDINE ANTAGONISTS AND METHODS OF USE | |
| EA201991577A1 (en) | NEW ANTIBODIES AGAINST THE HUMAN TRANSFERRIN RECEPTOR, ABLE TO BREAK THE HEMATOENCEPHALIC BARRIER | |
| CY1120414T1 (en) | ANTIBODIES CONNECTED TO NO40 AND THEIR USES | |
| CO6231038A2 (en) | UNION PROTEINS, INCLUDING ANTIBODIES DERIVED FROM ANTIBODY AND ANTIBODY FRAGMENTS THAT SPECIFICALLY JOIN CD154 AND ITS USES | |
| ES2657443T3 (en) | Anti-GITR antibodies and uses thereof | |
| BR0314814A (en) | Optimized variants of fc and methods for their generation | |
| AR109355A2 (en) | OX40 HUMAN RECEIVER UNION MOLECULES | |
| CO6231009A2 (en) | ANTIBODIES OX40 ANTAGONISTS AND ITS USE IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | |
| CR20110544A (en) | SPECIFIC ANTAGONIST ANTIBODY FOR THE ALFA-4-BETA-7 HETERODYMER | |
| BR122018016045B8 (en) | optimized variant protein | |
| ES2685823T3 (en) | Anti-CD40 antagonist antibodies | |
| AR083747A1 (en) | ANTI-IL-23 ANTIBODIES | |
| RS52889B (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
| RS52782B (en) | High affinity human antibodies to human il-4 receptor | |
| PE20180042A1 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USING THEM | |
| CU20120095A7 (en) | PCSK9 ANTAGONISTS | |
| CO6220978A2 (en) | ANTIBODIES DIRECTED TO PROTEIN-1 CHEMIO-TACTICS OF MONOCITS (MCP-1) AND ITS USES | |
| AR081750A1 (en) | ANTI-CD40 ANTIBODIES | |
| PE20090763A1 (en) | POLYPETIDES, VARIABLE DOMAINS OF ANTIBODIES AND ANTAGONISTS | |
| RS53750B1 (en) | Notch1 receptor binding agents and methods of use thereof | |
| PE20130393A1 (en) | ANTIBODIES WITH PH-DEPENDENT ANTIGEN UNION | |
| RS54133B1 (en) | Anti-il-6 antibodies, compositions, methods and uses | |
| RS53793B1 (en) | Humanized antibodies to amyloid beta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |